These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37864443)

  • 101. The role of minimal residual disease in chronic lymphocytic leukemia.
    Al-Sawaf O; Hallek M; Fischer K
    Clin Adv Hematol Oncol; 2022 Feb; 20(2):97-103. PubMed ID: 35120090
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
    Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
    Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
    [TBL] [Abstract][Full Text] [Related]  

  • 103. The evolving use of measurable residual disease in chronic lymphocytic leukemia clinical trials.
    Fisher A; Goradia H; Martinez-Calle N; Patten P; Munir T
    Front Oncol; 2023; 13():1130617. PubMed ID: 36910619
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Optimization and Validation of an 8-Color Single-Tube Assay for the Sensitive Detection of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia Detected via Flow Cytometry.
    Dowling AK; Liptrot SD; O'Brien D; Vandenberghe E
    Lab Med; 2016 May; 47(2):103-11. PubMed ID: 27069028
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Performance of a novel eight-color flow cytometry panel for measurable residual disease assessment of chronic lymphocytic leukemia.
    Chen X; Chen X; Zhao S; Shi Y; Zhang N; Guo Z; Qiao C; Jin H; Zhu L; Zhu H; Li J; Wu Y
    Cytometry B Clin Cytom; 2024 May; 106(3):181-191. PubMed ID: 38535092
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR.
    Raponi S; Della Starza I; De Propris MS; Del Giudice I; Mauro FR; Marinelli M; Di Maio V; Piciocchi A; Foà R; Guarini A
    Br J Haematol; 2014 Aug; 166(3):360-8. PubMed ID: 24735016
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Performance of eight-color dry antibody reagent in the detection of minimal residual disease in chronic lymphocytic leukemia samples.
    Bento L; Correia R; de Sousa F; Vaz A; Pedro E; Schimidell D; Millan N; Passaro M; Barroso R; Bacal N
    Cytometry B Clin Cytom; 2020 Nov; 98(6):529-535. PubMed ID: 32251553
    [TBL] [Abstract][Full Text] [Related]  

  • 108. 14-Color single tube for flow cytometric characterization of CD5+ B-LPDs and high sensitivity automated minimal residual disease quantitation of CLL/SLL.
    Goshaw JM; Gao Q; Wardrope J; Dogan A; Roshal M
    Cytometry B Clin Cytom; 2021 Jul; 100(4):509-518. PubMed ID: 32896973
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Principal component analysis yields results comparable to those of an elaborate Boolean strategy: simplifying the assessment of measurable residual disease in chronic lymphocytic leukemia patients.
    Brett VE; Dilhuydy MS; Lechevalier N; Adjibabi AN; Gros FX; Forcade É; Letestu R; Vial JP
    Ann Biol Clin (Paris); 2023 Oct; 81(4):379-387. PubMed ID: 37864443
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Measurable residual disease in the treatment of chronic lymphocytic leukemia.
    Uchiyama T; Yokoyama A; Aoki S
    J Clin Exp Hematop; 2020 Dec; 60(4):138-145. PubMed ID: 33148932
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.
    Montillo M; Schinkoethe T; Elter T
    Cancer Invest; 2005; 23(6):488-96. PubMed ID: 16203656
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand?
    D'Arena G; Sgambato A; Volpe S; Coppola G; Amodeo R; Tirino V; D'Auria F; Statuto T; Valvano L; Pietrantuono G; Deaglio S; Efremov D; Laurenti L; Aiello A
    Hematol Oncol; 2022 Dec; 40(5):835-842. PubMed ID: 35667043
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Assessing minimal residual disease in chronic lymphocytic leukemia.
    Rawstron AC; Hillmen P
    Curr Hematol Malig Rep; 2008 Jan; 3(1):47-53. PubMed ID: 20425446
    [TBL] [Abstract][Full Text] [Related]  

  • 114.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 115.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 116.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 117.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 118.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 119.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 120.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.